The placenta: A main role in congenital toxoplasmosis?

Trends in Parasitology

Volumn 27, Issue 12, 2011, Pages 530-536

  Robert Gangneux, Florence ^a,b   Murat, Jean Benjamin ^c,d   Fricker Hidalgo, Hélène ^c,d   Brenier Pinchart, Marie Pierre ^c,d   Gangneux, Jean Pierre ^a,b   Pelloux, Hervé ^c,d  

^a RENNES UNIVERSITY HOSPITAL   (France)

^b UNIVERSITÉ DE RENNES 1   (France)

^c GRENOBLE UNIVERSITY HOSPITAL   (France)

^d UNIV GRENOBLE ALPES   (France)

Author keywords

[No Author keywords available]

Indexed keywords

AZITHROMYCIN; FOLINIC ACID; PYRIMETHAMINE SULFADIAZINE; SPIRAMYCIN;

CONGENITAL TOXOPLASMOSIS; DELIVERY; HUMAN; MATERNAL TREATMENT; MICROORGANISM DETECTION; NONHUMAN; PATHOPHYSIOLOGY; PLACENTA; PLACENTAL TRANSFER; PREGNANCY; REVIEW; TOXOPLASMA GONDII;

ANIMALS; ANTIPARASITIC AGENTS; FEMALE; FETUS; HUMANS; INFECTIOUS DISEASE TRANSMISSION, VERTICAL; MICE; PARASITE LOAD; PLACENTA; PREDICTIVE VALUE OF TESTS; PREGNANCY; PREGNANCY COMPLICATIONS, PARASITIC; TOXOPLASMA; TOXOPLASMOSIS; TOXOPLASMOSIS, CONGENITAL;

TOXOPLASMA GONDII;

EID: 82855171666     PISSN: 14714922     EISSN: 14715007     Source Type: Journal    
DOI: 10.1016/j.pt.2011.09.005     Document Type: Review

References (63)

1. Entrican G. Immune regulation during pregnancy and host-pathogen interactions in infectious abortion. J. Comp. Pathol. 2002, 126:79-94.
2. Lambert H., Barragan A. Modelling parasite dissemination: host cell subversion and immune evasion by Toxoplasma gondii. Cell Microbiol. 2010, 12:292-300.
3. Abbasi M., et al. Infection of placental trophoblasts by Toxoplasma gondii. J. Infect. Dis. 2003, 188:608-616.
4. Yap G., et al. Cutting edge: IL-12 is required for the maintenance of IFN-gamma production in T cells mediating chronic resistance to the intracellular pathogen, Toxoplasma gondii. J. Immunol. 2000, 165:628-631.
5. Denkers E.Y. T lymphocyte-dependent effector mechanisms of immunity to Toxoplasma gondii. Microbes Infect. 1999, 1:699-708.
6. Barbosa B.F., et al. BeWo trophoblast cell susceptibility to Toxoplasma gondii is increased by interferon-gamma, interleukin-10 and transforming growth factor-beta1. Clin. Exp. Immunol. 2008, 151:536-545.
7. Pfaff A.W., et al. Cellular and molecular physiopathology of congenital toxoplasmosis: the dual role of IFN-gamma. Parasitology 2007, 134:1895-1902.
8. Shiono Y., et al. Maternal-fetal transmission of Toxoplasma gondii in interferon-gamma deficient pregnant mice. Parasitol. Int. 2007, 56:141-148.
9. Hackmon R., et al. Reduced third-trimester levels of soluble human leukocyte antigen G protein in severe preeclampsia. Am. J. Obstet. Gynecol. 2007, 197:255.
10. Pfaff A.W., et al. Impact of foetus and mother on IFN-gamma-induced indoleamine 2,3-dioxygenase and inducible nitric oxide synthase expression in murine placenta following Toxoplasma gondii infection. Int. J. Parasitol. 2008, 38. e1-5, 249-258.
11. Pfaff A.W., et al. Toxoplasma gondii regulates ICAM-1 mediated monocyte adhesion to trophoblasts. Immunol. Cell Biol. 2005, 83:483-489.
12. Juliano P.B., et al. ICAM-1 is overexpressed by villous trophoblasts in placentitis. Placenta 2006, 27:750-757.
13. Barragan A., et al. Transepithelial migration of Toxoplasma gondii involves an interaction of intercellular adhesion molecule 1 (ICAM-1) with the parasite adhesin MIC2. Cell Microbiol. 2005, 7:561-568.
14. Carruthers V., Boothroyd J.C. Pulling together: an integrated model of Toxoplasma cell invasion. Curr. Opin. Microbiol. 2007, 10:83-89.
15. Hunt J.S., et al. HLA-G and immune tolerance in pregnancy. FASEB J. 2005, 19:681-693.
16. Robert-Gangneux F., et al. High level of soluble HLA-G in amniotic fluid is correlated with congenital transmission of Toxoplasma gondii. Clin. Immunol. 2011, 138:129-134.
17. Couvreur J., et al. Prophylaxis of congenital toxoplasmosis. Effects of spiramycin on placental infection. J. Antimicrob. Chemother. 1988, 22(Suppl. B):193-200.
18. Desmonts G., Couvreur J. Congenital toxoplasmosis. A prospective study of 378 pregnancies. N. Engl. J. Med. 1974, 290:1110-1116.
19. Couvreur J., et al. In utero treatment of toxoplasmic fetopathy with the combination pyrimethamine-sulfadiazine. Fetal Diagn. Ther. 1993, 8:45-50.
20. Gratzl R., et al. Treatment of toxoplasmosis in pregnancy: concentrations of spiramycin and neospiramycin in maternal serum and amniotic fluid. Eur. J. Clin. Microbiol. Infect. Dis. 2002, 21:12-16.
21. Schoondermark-Van de Ven E., et al. Effectiveness of spiramycin for treatment of congenital Toxoplasma gondii infection in rhesus monkeys. Antimicrob. Agents Chemother. 1994, 38:1930-1936.
22. Schoondermark-Van de Ven E., et al. Pharmacokinetics of spiramycin in the rhesus monkey: transplacental passage and distribution in tissue in the fetus. Antimicrob. Agents Chemother. 1994, 38:1922-1929.
23. Montoya J.G., Remington J.S. Management of Toxoplasma gondii infection during pregnancy. Clin. Infect. Dis. 2008, 47:554-566.
24. Schoondermark-van de Ven E.M., et al. Prenatal diagnosis and treatment of congenital Toxoplasma gondii infections: an experimental study in rhesus monkeys. Eur. J. Obstet. Gynecol. Reprod. Biol. 1997, 74:183-188.
25. Schoondermark-van de Ven E., et al. Study of treatment of congenital Toxoplasma gondii infection in rhesus monkeys with pyrimethamine and sulfadiazine. Antimicrob. Agents Chemother. 1995, 39:137-144.
26. Costa I.N., et al. Azithromycin inhibits vertical transmission of Toxoplasma gondii in Calomys callosus (Rodentia: Cricetidae). Placenta 2009, 30:884-890.
27. Wallon M., et al. Congenital toxoplasmosis: systematic review of evidence of efficacy of treatment in pregnancy. BMJ 1999, 318:1511-1514.
28. Thiebaut R., et al. Effectiveness of prenatal treatment for congenital toxoplasmosis: a meta-analysis of individual patients' data. Lancet 2007, 369:115-122.
29. Foulon W., et al. Treatment of toxoplasmosis during pregnancy: a multicenter study of impact on fetal transmission and children's sequelae at age 1 year. Am. J. Obstet. Gynecol. 1999, 180:410-415.
30. Gilbert R.E., et al. Effect of prenatal treatment on mother to child transmission of Toxoplasma gondii: retrospective cohort study of 554 mother-child pairs in Lyon, France. Int. J. Epidemiol. 2001, 30:1303-1308.
31. Gilbert R., Gras L. Effect of timing and type of treatment on the risk of mother to child transmission of Toxoplasma gondii. BJOG 2003, 110:112-120.
32. Bessieres M.H., et al. Neonatal screening for congenital toxoplasmosis in a cohort of 165 women infected during pregnancy and influence of in utero treatment on the results of neonatal tests. Eur. J. Obstet. Gynecol. Reprod. Biol. 2001, 94:37-45.
33. Gras L., et al. Association between prenatal treatment and clinical manifestations of congenital toxoplasmosis in infancy: a cohort study in 13 European centres. Acta Paediatr. 2005, 94:1721-1731.
34. Cortina-Borja M., et al. Prenatal treatment for serious neurological sequelae of congenital toxoplasmosis: an observational prospective cohort study. PLoS Med. 2010, 7. pii: e1000351.
35. Thulliez P. Commentary: Efficacy of prenatal treatment for toxoplasmosis: a possibility that cannot be ruled out. Int. J. Epidemiol. 2001, 30:1315-1316.
36. McLeod R., et al. Why prevent, diagnose and treat congenital toxoplasmosis?. Mem. Inst. Oswaldo Cruz 2009, 104:320-344.
37. Chene G., Thiebaut R. Options for clinical trials of pre and post-natal treatments for congenital toxoplasmosis. Mem. Inst. Oswaldo Cruz 2009, 104:299-304.
38. Gilbert R. Treatment for congenital toxoplasmosis: finding out what works. Mem. Inst. Oswaldo Cruz 2009, 104:305-311.
39. Romand S., et al. Prenatal diagnosis using polymerase chain reaction on amniotic fluid for congenital toxoplasmosis. Obstet. Gynecol. 2001, 97:296-300.
40. Fricker-Hidalgo H., et al. Congenital toxoplasmosis: specific IgM in fetal blood, cord blood and in the newborn. Ann. Biol. Clin. (Paris) 1996, 54:165-168.
41. Fricker-Hidalgo H., et al. Detection of Toxoplasma gondii in 94 placentae from infected women by polymerase chain reaction, in vivo, and in vitro cultures. Placenta 1998, 19:545-549.
42. Naessens A., et al. Diagnosis of congenital toxoplasmosis in the neonatal period: a multicenter evaluation. J. Pediatr. 1999, 135:714-719.
43. Fricker-Hidalgo H., et al. Value of Toxoplasma gondii detection in one hundred thirty-three placentas for the diagnosis of congenital toxoplasmosis. Pediatr. Infect. Dis. J. 2007, 26:845-846.
44. Robert-Gangneux F., et al. Value of prenatal diagnosis and early postnatal diagnosis of congenital toxoplasmosis: retrospective study of 110 cases. J. Clin. Microbiol. 1999, 37:2893-2898.
45. Robert-Gangneux F., et al. Clinical relevance of placenta examination for the diagnosis of congenital toxoplasmosis. Pediatr. Infect. Dis. J. 2010, 29:33-38.
46. Filisetti D., et al. Placental testing for Toxoplasma gondii is not useful to diagnose congenital toxoplasmosis. Pediatr. Infect. Dis. J. 2010, 29:665-667.
47. Burg J.L., et al. Direct and sensitive detection of a pathogenic protozoan, Toxoplasma gondii, by polymerase chain reaction. J. Clin. Microbiol. 1989, 27:1787-1792.
48. Wallon M., et al. Accuracy of real-time polymerase chain reaction for Toxoplasma gondii in amniotic fluid. Obstet. Gynecol. 2010, 115:727-733.
49. Ajzenberg D., et al. Genotype of 86 Toxoplasma gondii isolates associated with human congenital toxoplasmosis, and correlation with clinical findings. J. Infect. Dis. 2002, 186:684-689.
50. Pinon J.M., et al. Early neonatal diagnosis of congenital toxoplasmosis: value of comparative enzyme-linked immunofiltration assay immunological profiles and anti-Toxoplasma gondii immunoglobulin M (IgM) or IgA immunocapture and implications for postnatal therapeutic strategies. J. Clin. Microbiol. 1996, 34:579-583.
51. Pinon J.M., et al. Strategy for diagnosis of congenital toxoplasmosis: evaluation of methods comparing mothers and newborns and standard methods for postnatal detection of immunoglobulin G, M, and A antibodies. J. Clin. Microbiol. 2001, 39:2267-2271.
52. Tissot Dupont D., et al. Usefulness of Western blot in serological follow-up of newborns suspected of congenital toxoplasmosis. Eur. J. Clin. Microbiol. Infect. Dis. 2003, 22:122-125.
53. Robert-Gangneux F., et al. Congenital toxoplasmosis after a preconceptional or periconceptional maternal infection. Pediatr. Infect. Dis. J. 2009, 28:660-661.
54. Bessieres M.H., et al. Diagnosis of congenital toxoplasmosis: prenatal and neonatal evaluation of methods used in Toulouse University Hospital and incidence of congenital toxoplasmosis. Mem. Inst. Oswaldo Cruz 2009, 104:389-392.
55. Sibley L.D., Ajioka J.W. Population structure of Toxoplasma gondii: clonal expansion driven by infrequent recombination and selective sweeps. Annu. Rev. Microbiol. 2008, 62:329-351.
56. Darde M.L. Toxoplasma gondii, " new" genotypes and virulence. Parasite 2008, 15:366-371.
57. Delhaes L., et al. Severe congenital toxoplasmosis due to a Toxoplasma gondii strain with an atypical genotype: case report and review. Prenat. Diagn. 2010, 30:902-905.
58. Demar M., et al. Fatal outbreak of human toxoplasmosis along the Maroni River: epidemiological, clinical, and parasitological aspects. Clin. Infect. Dis. 2007, 45:e88-e95.
59. Meneceur P., et al. In vitro susceptibility of various genotypic strains of Toxoplasma gondii to pyrimethamine, sulfadiazine, and atovaquone. Antimicrob. Agents Chemother. 2008, 52:1269-1277.
60. Brenier-Pinchart M.P., et al. In vitro differential phenotypic characteristics among type-II Toxoplasma gondii strains from congenital toxoplasmosis in humans. J. Parasitol. 2010, 96:798-799.
61. Bougdour A., et al. Drug inhibition of HDAC3 and epigenetic control of differentiation in Apicomplexa parasites. J. Exp. Med. 2009, 206:953-966.
62. Senegas A., et al. Toxoplasma gondii-induced foetal resorption in mice involves interferon-gamma-induced apoptosis and spiral artery dilation at the maternofoetal interface. Int. J. Parasitol. 2009, 39:481-487.
63. Pfaff A.W., Candolfi E. New insights in toxoplasmosis immunology during pregnancy. Perspective for vaccine prevention. Parassitologia 2008, 50:55-58.